Eterna Therapeutics Ownership 2024 | Who Owns Eterna Therapeutics Now?


OverviewRevenueFinancialsChart

Institutional Ownership

10.43%

Insider Ownership

39.31%

Retail Ownership

50.26%

Institutional Holders

18.00

Eterna Therapeutics Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
CYPRESS POINT WEALTH MANAGEMENT, LLC3.09%0.45%94,375--320,875,000Mar 31, 2023
NAVITER WEALTH, LLC2.61%0.09%79,666450.06%270,864,000Mar 31, 2023
CI PRIVATE WEALTH, LLC2.01%0.00%61,189--214,071,000Mar 31, 2023
BLACKROCK INC.0.77%-23,3632220.96%79,434,000Mar 31, 2023
VANGUARD GROUP INC0.63%-19,068-10,000-34.40%64,831,000Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC0.46%-13,985--48,947,000Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC0.43%0.00%13,053-4,483-25.56%44,000Mar 31, 2023
BALDWIN BROTHERS LLC/MA0.31%0.00%9,4702783.02%32,198,000Mar 31, 2023
UBS GROUP AG0.13%-3,8643,864100.00%13,138,000Mar 31, 2023
CARMICHAEL HILL & ASSOCIATES, INC.0.00%0.00%75--255,000Mar 31, 2023
MONTAG A & ASSOCIATES INC0.00%-70--238,000Mar 31, 2023
MORGAN STANLEY0.00%-50-1,313-96.33%170,000Mar 31, 2023
GROUP ONE TRADING, L.P.0.00%-19--67,000Mar 31, 2023
WELLS FARGO & COMPANY/MN0.00%-16-10-38.46%54,000Mar 31, 2023
CITIGROUP INC0.00%-15--53,000Mar 31, 2023
ASPIRE PRIVATE CAPITAL, LLC0.00%-10--34,000Mar 31, 2023
BANK OF AMERICA CORP /DE/0.00%-9--31,000Mar 31, 2023
FMR LLC--1--4,000Mar 31, 2023
CREDIT SUISSE AG/----120-100.00%-Mar 31, 2023

Eterna Therapeutics's largest institutional shareholder is CYPRESS POINT WEALTH MANAGEMENT, LLC, holding 3.09% of the company's total share outstanding, currently valued at $320.88M. The top 10 institutional shareholders own together 10.43% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
CYPRESS POINT WEALTH MANAGEMENT, LLC3.09%0.45%94,375--320,875,000Mar 31, 2023
NAVITER WEALTH, LLC2.61%0.09%79,666450.06%270,864,000Mar 31, 2023
BALDWIN BROTHERS LLC/MA0.31%0.00%9,4702783.02%32,198,000Mar 31, 2023
CI PRIVATE WEALTH, LLC2.01%0.00%61,189--214,071,000Mar 31, 2023
CARMICHAEL HILL & ASSOCIATES, INC.0.00%0.00%75--255,000Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC0.43%0.00%13,053-4,483-25.56%44,000Mar 31, 2023
MONTAG A & ASSOCIATES INC0.00%-70--238,000Mar 31, 2023
ASPIRE PRIVATE CAPITAL, LLC0.00%-10--34,000Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC0.46%-13,985--48,947,000Mar 31, 2023
UBS GROUP AG0.13%-3,8643,864100.00%13,138,000Mar 31, 2023
BLACKROCK INC.0.77%-23,3632220.96%79,434,000Mar 31, 2023
VANGUARD GROUP INC0.63%-19,068-10,000-34.40%64,831,000Mar 31, 2023
GROUP ONE TRADING, L.P.0.00%-19--67,000Mar 31, 2023
CITIGROUP INC0.00%-15--53,000Mar 31, 2023
MORGAN STANLEY0.00%-50-1,313-96.33%170,000Mar 31, 2023
WELLS FARGO & COMPANY/MN0.00%-16-10-38.46%54,000Mar 31, 2023
BANK OF AMERICA CORP /DE/0.00%-9--31,000Mar 31, 2023
FMR LLC--1--4,000Mar 31, 2023
CREDIT SUISSE AG/----120-100.00%-Mar 31, 2023

The largest Eterna Therapeutics shareholder by % of total assets is CYPRESS POINT WEALTH MANAGEMENT, LLC. The company owns 94.38K shares of Eterna Therapeutics (ERNA), representing 0.45% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
UBS GROUP AG0.13%-3,8643,864100.00%13,138,000Mar 31, 2023
BALDWIN BROTHERS LLC/MA0.31%0.00%9,4702783.02%32,198,000Mar 31, 2023
BLACKROCK INC.0.77%-23,3632220.96%79,434,000Mar 31, 2023
NAVITER WEALTH, LLC2.61%0.09%79,666450.06%270,864,000Mar 31, 2023
FMR LLC--1--4,000Mar 31, 2023
BANK OF AMERICA CORP /DE/0.00%-9--31,000Mar 31, 2023
CITIGROUP INC0.00%-15--53,000Mar 31, 2023
GROUP ONE TRADING, L.P.0.00%-19--67,000Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC0.46%-13,985--48,947,000Mar 31, 2023
ASPIRE PRIVATE CAPITAL, LLC0.00%-10--34,000Mar 31, 2023
MONTAG A & ASSOCIATES INC0.00%-70--238,000Mar 31, 2023
CARMICHAEL HILL & ASSOCIATES, INC.0.00%0.00%75--255,000Mar 31, 2023
CI PRIVATE WEALTH, LLC2.01%0.00%61,189--214,071,000Mar 31, 2023
CYPRESS POINT WEALTH MANAGEMENT, LLC3.09%0.45%94,375--320,875,000Mar 31, 2023
WELLS FARGO & COMPANY/MN0.00%-16-10-38.46%54,000Mar 31, 2023
CREDIT SUISSE AG/----120-100.00%-Mar 31, 2023
MORGAN STANLEY0.00%-50-1,313-96.33%170,000Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC0.43%0.00%13,053-4,483-25.56%44,000Mar 31, 2023
VANGUARD GROUP INC0.63%-19,068-10,000-34.40%64,831,000Mar 31, 2023

As of Mar 31 2023, Eterna Therapeutics's largest institutional buyer is UBS GROUP AG. The company purchased 3.86K stocks of ERNA, valued at $13.14M.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
VANGUARD GROUP INC0.63%-19,068-10,000-34.40%64,831,000Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC0.43%0.00%13,053-4,483-25.56%44,000Mar 31, 2023
MORGAN STANLEY0.00%-50-1,313-96.33%170,000Mar 31, 2023
CREDIT SUISSE AG/----120-100.00%-Mar 31, 2023
WELLS FARGO & COMPANY/MN0.00%-16-10-38.46%54,000Mar 31, 2023
CYPRESS POINT WEALTH MANAGEMENT, LLC3.09%0.45%94,375--320,875,000Mar 31, 2023
CI PRIVATE WEALTH, LLC2.01%0.00%61,189--214,071,000Mar 31, 2023
CARMICHAEL HILL & ASSOCIATES, INC.0.00%0.00%75--255,000Mar 31, 2023
MONTAG A & ASSOCIATES INC0.00%-70--238,000Mar 31, 2023
ASPIRE PRIVATE CAPITAL, LLC0.00%-10--34,000Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC0.46%-13,985--48,947,000Mar 31, 2023
GROUP ONE TRADING, L.P.0.00%-19--67,000Mar 31, 2023
CITIGROUP INC0.00%-15--53,000Mar 31, 2023
BANK OF AMERICA CORP /DE/0.00%-9--31,000Mar 31, 2023
FMR LLC--1--4,000Mar 31, 2023
NAVITER WEALTH, LLC2.61%0.09%79,666450.06%270,864,000Mar 31, 2023
BLACKROCK INC.0.77%-23,3632220.96%79,434,000Mar 31, 2023
BALDWIN BROTHERS LLC/MA0.31%0.00%9,4702783.02%32,198,000Mar 31, 2023
UBS GROUP AG0.13%-3,8643,864100.00%13,138,000Mar 31, 2023

As of Mar 31 2023, Eterna Therapeutics's biggest institutional seller is VANGUARD GROUP INC. The company sold -10.00K shares of ERNA, valued at $64.83M.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
UBS GROUP AG0.13%-3,8643,864100.00%13,138,000Mar 31, 2023

Eterna Therapeutics's largest new institutional shareholder by number of shares is UBS GROUP AG, purchased 3.86K shares, valued at $13.14M, as of undefined.

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
CREDIT SUISSE AG/----120-100.00%-Mar 31, 2023

Eterna Therapeutics's largest sold out institutional shareholder by shares sold is CREDIT SUISSE AG/, sold -0.12K shares, valued at -, as of undefined.

Eterna Therapeutics Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
VANGUARD INDEX FUNDS0.00%52,19827,300109.65%Dec 31, 2023
DFA INVESTMENT DIMENSIONS GROUP INC0.00%5,904--Jan 31, 2024
PROSHARES TRUST0.00%247--Feb 29, 2024
EQ ADVISORS TRUST0.00%476--Dec 31, 2023

Eterna Therapeutics's largest mutual fund holder by % of total assets is "VANGUARD INDEX FUNDS", owning 52.20K shares, compromising 0.00% of its total assets.

Eterna Therapeutics Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
31 Mar, 2318-
31 Dec, 2218-

As of 31 Mar 23, 18 institutions are holding Eterna Therapeutics's shares, representing an increase of 0.00% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Mar, 23318,298-3.49%
31 Dec, 22329,815-

Eterna Therapeutics (ERNA) has 318.30K shares outstanding as of 31 Mar 23, down -3.49% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Mar, 2310.43%-6.97%
31 Dec, 2211.21%-

As of 31 Mar 23, Eterna Therapeutics is held by 10.43% institutional shareholders, representing a -6.97% negative growth compared to 31 Dec 22.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Mar, 233-
31 Dec, 22--

3 institutional shareholders have increased their position in ERNA stock as of 31 Mar 23 compared to - in the previous quarter (a 0.00% increase).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Mar, 234-
31 Dec, 22--

4 institutional shareholders have reduced their position in ERNA stock as of 31 Mar 23 compared to - in the previous quarter (a 0.00% increase).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Mar, 2318-318,298-3.49%10.43%-6.97%3-4-
31 Dec, 2218-329,815-11.21%-----

Eterna Therapeutics Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Dec 20, 2023Cherington Charles10 percent owner-P-PurchaseBuy3,125,976$1.43$4.47M3,125,976
Dec 20, 2023Cherington Charles10 percent owner-P-PurchaseBuy2,307,692$1.43$3.30M2,307,692
Dec 20, 2023Cherington Charles10 percent owner-P-PurchaseBuy523,512$1.43$748.62K523,512
Dec 20, 2023Cherington Charles10 percent owner-P-PurchaseBuy-$1.92--
Dec 18, 2023Freebird Partners LP10 percent owner-P-PurchaseBuy1,041,992$1.43$1.49M1,991,394
Dec 18, 2023Freebird Partners LP10 percent owner-P-PurchaseBuy520,996$1.92$1000.00K783,233

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Dec 20, 2023Cherington Charles10 percent owner-P-PurchaseBuy3,125,976$1.43$4.47M3,125,976
Dec 20, 2023Cherington Charles10 percent owner-P-PurchaseBuy2,307,692$1.43$3.30M2,307,692
Dec 20, 2023Cherington Charles10 percent owner-P-PurchaseBuy523,512$1.43$748.62K523,512
Dec 20, 2023Cherington Charles10 percent owner-P-PurchaseBuy-$1.92--
Dec 18, 2023Freebird Partners LP10 percent owner-P-PurchaseBuy1,041,992$1.43$1.49M1,991,394
Dec 18, 2023Freebird Partners LP10 percent owner-P-PurchaseBuy520,996$1.92$1000.00K783,233

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Dec 20, 2023Cherington Charles10 percent owner-H-ExpireLongSell2,307,692$2.61$6.02M-
Dec 20, 2023Cherington Charles10 percent owner-H-ExpireLongSell523,512$3.28$1.72M-

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Apr 29, 2024Cicala Peterdirector-A-AwardBuy88,946$1.74$154.77K88,946
Apr 29, 2024Gurrola Sandra Mofficer Sr. VP of FinanceA-AwardBuy80,000$1.74$139.20K80,000
Apr 29, 2024Bristol James Arthurdirector-A-AwardBuy124,525$1.74$216.67K124,525
Feb 16, 2024Cicala Peter-Buy----
Jan 03, 2024Luther Sanjeevdirector, officer President and CEOA-AwardBuy1,685,218$1.80$3.03M1,685,218
Jan 03, 2024Clarke Dorothy Jdirector, officer General CounselA-AwardBuy168,521$1.80$303.34K168,521
Jan 03, 2024Luther Sanjeev-Buy----
Dec 20, 2023Cherington Charles10 percent owner-P-PurchaseBuy3,125,976$1.43$4.47M3,125,976
Dec 20, 2023Cherington Charles10 percent owner-P-PurchaseBuy2,307,692$1.43$3.30M2,307,692
Dec 20, 2023Cherington Charles10 percent owner-P-PurchaseBuy523,512$1.43$748.62K523,512
Dec 20, 2023Cherington Charles10 percent owner-P-PurchaseBuy-$1.92--
Dec 20, 2023Cherington Charles10 percent owner-H-ExpireLongSell2,307,692$2.61$6.02M-
Dec 20, 2023Cherington Charles10 percent owner-H-ExpireLongSell523,512$3.28$1.72M-
Dec 18, 2023Freebird Partners LP10 percent owner-P-PurchaseBuy1,041,992$1.43$1.49M1,991,394
Dec 18, 2023Freebird Partners LP10 percent owner-A-AwardBuy524,474$1.43$750.00K949,402
Dec 18, 2023Freebird Partners LP10 percent owner-P-PurchaseBuy520,996$1.92$1000.00K783,233
Dec 18, 2023Freebird Partners LP10 percent owner-D-ReturnBuy424,928$3.28$1.39M524,474
Dec 18, 2023Freebird Partners LP10 percent owner-D-ReturnBuy524,474$2.61$1.37M424,928
Nov 13, 2023Bristol James Arthur-Buy----
Sep 01, 2023Clarke Dorothy J-Buy----

The last insider sell of Eterna Therapeutics's stock was made by Cherington Charles on Dec 20 2023, selling 2,307,692 shares at $2.61 per share (valued at $6.02M). The last insider buy of ERNA was made by Cherington Charles on Dec 20 2023, buying 3,125,976 shares at $1.43 per share (worth $4.47M).

Eterna Therapeutics Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q1 20242--
Q4 202392450.00%
Q3 20238--
Q2 20231425.00%
Q1 20231--
Q4 2022-1-
Q3 202211100.00%

2 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Eterna Therapeutics's insiders, as of Q1 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q1 2024---
Q4 20236--
Q3 20238--
Q2 2023---
Q1 2023---
Q4 2022---
Q3 2022---

As of Q1 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Eterna Therapeutics's stocks.

Eterna Therapeutics Peer Ownership


TickerCompany
ZURAZura Bio Limited
ZVSAZyVersa Therapeutics, Inc.
ABOSAcumen Pharmaceuticals, Inc.
TCRXTScan Therapeutics, Inc.
RLAYRelay Therapeutics, Inc.
RNAZTransCode Therapeutics, Inc.
PALIPalisade Bio, Inc.
VECTVectivBio Holding AG
RCUSArcus Biosciences, Inc.
XFORX4 Pharmaceuticals, Inc.
UNCYUnicycive Therapeutics, Inc.
ITOSiTeos Therapeutics, Inc.
INZYInozyme Pharma, Inc.
IMMXImmix Biopharma, Inc.
DAWNDay One Biopharmaceuticals, Inc.
ANNXAnnexon, Inc.
GPCRStructure Therapeutics Inc.
CGEMCullinan Oncology, Inc.
REVBRevelation Biosciences, Inc.
PHIOPhio Pharmaceuticals Corp.
APLSApellis Pharmaceuticals, Inc.

ERNA Ownership FAQ


Eterna Therapeutics is owned by institutional shareholders (10.43%), insiders (39.31%), and public (50.26%). The largest institutional shareholder of Eterna Therapeutics is CYPRESS POINT WEALTH MANAGEMENT, LLC (3.09% of total shares) and the top mutual fund owner is VANGUARD INDEX FUNDS (0.00% of total shares).

Eterna Therapeutics's major institutional shareholders are CYPRESS POINT WEALTH MANAGEMENT, LLC, NAVITER WEALTH, LLC, CI PRIVATE WEALTH, LLC, BLACKROCK INC., and VANGUARD GROUP INC. The top five shareholders own together 9.10% of the company's share outstanding.

As of Mar 2023, there are 18 institutional shareholders of Eterna Therapeutics.

CYPRESS POINT WEALTH MANAGEMENT, LLC owns 94.38K shares of Eterna Therapeutics, representing 3.09% of the company's total shares outstanding, valued at $320.88M (as of Mar 2023).

As of Mar 2023, NAVITER WEALTH, LLC holds 79.67K shares of Eterna Therapeutics (ERNA), compromising 2.61% of the company, valued at $270.86M.

CI PRIVATE WEALTH, LLC is the third largest holder of Eterna Therapeutics. The company owns 61.19K of the company's shares outstanding (worth $214.07M).